From virus to diabetes therapy: Characterization of a specific insulin-degrading enzyme inhibitor for diabetes treatment.
Nash Y, Ganoth A, Borenstein-Auerbach N, Levy-Barazany H, Goldsmith G, Kopelevich A, Pozyuchenko K, Sakhneny L, Lazdon E, Blanga-Kanfi S, Alhadeff R, Benromano T, Landsman L, Tsfadia Y, Frenkel D.
Nash Y, et al. Among authors: alhadeff r.
FASEB J. 2021 May;35(5):e21374. doi: 10.1096/fj.201901945R.
FASEB J. 2021.
PMID: 33835493